



City of Hope's Abstract Presentations

AT THE AACR® ANNUAL
MEETING 2025

April 25 to 30, 2025
McCormick Place
Chicago, Illinois



VISIT US AT BOOTH NO. 2805.

cityofhope.org/aacr25

TOP 5 in the Nation for
Cancer Care*



AACR Annual Meeting 2025

Abstract Presentations

FRIDAY, APRIL 25, 2025

Time	Session Type	Location	Session Title	Presentation No.	Poster Board No.	Publishing Title	First Author/Presenter	Last Author
3:30 to 3:50 p.m.	Education Session	Room S106 — McCormick Place South (Level 1)	The Science and Art of Community Outreach and Engagement: Building Sustainable Healthy Communities			The science and art of community engagement for translating research into cancer-related policy and implementation: The Cancer Care Equity Act	Kimlin Tam Ashing, Ph.D.	
4:45 to 6:15 p.m.	Education Session	Room S100 A (Grand Ballroom A) — McCormick Place South (Level 1)	Accelerating Cancer Research with AI and Data Science: Multi-scale Multi-Modal Integration for Deeper Insights			Chair and Introduction	David W. Craig, Ph.D.	
4:45 to 6:15 p.m.	Education Session	Room S100 A (Grand Ballroom A) — McCormick Place South (Level 1)	Accelerating Cancer Research with AI and Data Science: Multi-scale Multi-Modal Integration for Deeper Insights			Resolving spatial subclonal genomic heterogeneity using the integration of multi-omic genomic approaches in solid tumors	David W. Craig, Ph.D.	

SATURDAY, APRIL 26, 2025

8 to 9:30 a.m.	Educational Session	Room S101 — McCormick Place South (Level 1)	Academic Entrepreneurship: Getting Your Discovery to Patients, Part 1 — Liftoff	ED54		Chair and Introduction	Michael A. Caligiuri, M.D.	
10 to 11:30 a.m.	Educational Session	Room S402 — McCormick Place South (Level 4)	Natural Killer Cells: Advances in Basic Biology and Clinical Applications	ED57		Chair and Introduction	Michael A. Caligiuri, M.D.	
10:01 to 10:21 a.m.	Educational Session	Room S402 — McCormick Place South (Level 4)	Natural Killer Cells: Advances in Basic Biology and Clinical Applications	ED57		Innate immune lymphocytes, including NK cells	Michael A. Caligiuri, M.D.	
5 to 7 p.m.	Professional Development Session	Great Lakes AB — Marriott Marquis Chicago	Personalized Career Conversations	PDS03		Chair	Christopher G. Sistrunk, Ph.D.	

SUNDAY, APRIL 27, 2025

Time	Session Type	Location	Session Title	Presentation No.	Poster Board No.	Publishing Title	First Author/Presenter	Last Author
2 to 5 p.m.	Poster Session	Section 17	Cell Cycle Effects of Anticancer Drugs	370	14	Resistance to sotorasib does not confer resistance to adagrasib: Why?	Atish Ranjan Mohanty, Ph.D.	Ravi Salgia, M.D., Ph.D.
2 to 5 p.m.	Poster Session	Section 26	Natural Products	599	1	Oligomeric proanthocyanidins overcome Lenvatinib resistance by targeting ITGA3 and EGFR-AKT pathways in hepatocellular carcinoma	Takayuki Noma, M.D.	Ajay Goel, Ph.D.
2 to 5 p.m.	Poster Session	Section 26	Natural Products	602	4	Synergistic anti-tumor effects of andrographis and lactoferrin in colorectal cancer via modulation of AXIN2/Wnt/E-cadherin signaling pathway	Yuan Li, Ph.D.	Ajay Goel, Ph.D.

All sessions are listed in Central Daylight Time. Schedules and locations are subject to change by AACR.

SUNDAY, APRIL 27, 2025

Time	Session Type	Location	Session Title	Presentation No.	Poster Board No.	Publishing Title	First Author/Presenter	Last Author
2 to 5 p.m.	Poster Session	Section 26	Natural Products	607	9	Andrographis and aronia berry extract synergistically exhibit anticancer effects in colorectal cancer by activating the p-YAP/PUMA signaling pathway	Kainan Wang, M.D.	Ajay Goel, Ph.D.
2 to 5 p.m.	Poster Session	Section 40	Viruses and Bacteria in Cancer Therapy	951	8	A novel oncolytic adenovirus platform with multi-gene immunomodulation for ovarian cancer treatment	Er Yue	Edward Wang, M.D., Ph.D.
2 to 5 p.m.	Poster Session	Section 41	Bridging Gaps in Cancer Care: Disparities, Social Determinants, Innovations, and Strategies	994	28	Advancing health equity and reducing disparities in prostate cancer in Black men: iCCaRE	Kimlin Tam Ashing, Ph.D.	
2 to 5 p.m.	Poster Session	Section 42	Genomic Diversity and Disparities in Cancer: Global Insights into Epidemiology, Risk, Outcomes, and Precision Medicine	1012	14	Investigating genetic and transcriptomic drivers of endometrial cancer disparities in Black/African American women	Danyelle Paine, Ph.D.	John D. Carpten, Ph.D.
2 to 5 p.m.	Poster Session	Section 43	Behavioral Sciences and Prevention, Screening, and Early Detection	1035	10	Western lifestyle leads to obesity and cancer via a common factor FTO	Dong Wu, Ph.D.	Jianjun Chen, Ph.D.
2 to 5 p.m.	Poster Session	Section 45	Bioinformatics, Computational Biology, and Systems Biology for Healthcare Equity	1056	10	Exploring the impact of ancestry on metabolic dysregulation in lung adenocarcinoma: Implications for racial health inequities and targeted therapeutics	Benecia A. Jackson	Aaron Neely, Ph.D., M.S., M.Sc.
2 to 5 p.m.	Poster Session	Section 47	Tumor Subtypes and Biomarker Discovery	1099	6	Leveraging RNA-seq for breast cancer survival analysis and risk stratification	Pooya Naseri-Nosar	Chi Wah Wong, Ph.D.
2 to 5 p.m.	Poster Session	Section 48	AACR Project GENIE Use Cases	1115	1	PM-AI agent: A conversational artificial intelligence system for precision medicine and advancing health equity through integrative clinical, genomic and social determinants of health data analysis	Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.	
2 to 5 p.m.	Poster Session	Section 48	AACR Project GENIE Use Cases	1120	6	Baseline biomarker analyses of patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the phase 3 CodeBreaK 300 study	Marwan Fakh, M.D.	
2 to 5 p.m.	Poster Session	Section 48	AACR Project GENIE Use Cases	1128	14	Comprehensive multi-omics analysis of colorectal cancer tumors in diverse populations	Brigette Waldrup	Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.
2 to 5 p.m.	LBA: Poster Session	Section 53	Late-Breaking Research: Tumor Biology 1	LB076	12	Spatial transcriptomics reveals differences in the tumor and immune microenvironment of high-grade serous ovarian cancers with differing responses to immune checkpoint inhibitors		John D. Carpten, Ph.D.
3:50 to 4 p.m.	Clinical Trials Minisymposium	Room S100 A (Grand Ballroom A) — McCormick Place South (Level 1)	ADCs and Immunooncology-focused Biological Approaches	CT011		Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)	Aditya Shreenivas, M.D.	
3:05 to 3:20 p.m.	Minisymposium	Room S103 — McCormick Place South (Level 1)	Artificial Intelligence and Machine Learning for Basic and Translational Research	1138		Decoding tumor microenvironment with deep learning: merging spatial transcriptomics and histopathology	Jiarong Song	David W. Craig, Ph.D.

All sessions are listed in Central Daylight Time. Schedules and locations are subject to change by AACR.

MONDAY, APRIL 28, 2025

Time	Session Type	Location	Session Title	Presentation No.	Poster Board No.	Publishing Title	First Author/Presenter	Last Author
9 a.m. to noon	Poster Session	Section 6	Radiation Sciences 1	1337	10	Androgen receptor mediates radioresistance through autophagy and DNA repair in AR-positive prostate cancer	Ken-ichi Kudo, Ph.D.	Yun Rose Li, M.D., Ph.D.
9 a.m. to noon	Poster Session	Section 12	Genome Maintenance: Mechanisms and Novel Therapeutics	1465	1	RAD52 and ERCC6L/PICH have a compensatory relationship for genome stability	Beth Osia, Ph.D.	Jeremy M. Stark, Ph.D.
9 a.m. to noon	Poster Session	Section 12	Genome Maintenance: Mechanisms and Novel Therapeutics	1479	15	Defining the interplay between DNAPKcs and shieldin during chromosomal break repair	Kaela Makins	Jeremy M. Stark, Ph.D.
9 a.m. to noon	Poster Session	Section 12	Genome Maintenance: Mechanisms and Novel Therapeutics	1484	20	USP36-governed p21 homeostasis confers radioresistance in pancreatic cancer	Haihua Feng, Ph.D.	Terence M. Williams, M.D., Ph.D.
9 a.m. to noon	Poster Session	Section 13	Hypoxia and Oxidative Stress	1512	17	EGR1 regulates phenotypic plasticity to promote breast cancer progression upon metabolic stress through elaborating HERPUD1-mediated unfolded protein response	Yi-Zhen Wu	
9 a.m. to noon	Poster Session	Section 27	Diagnostic Biomarkers 3: Early Detection Biomarkers	1902	2	Novel monoclonal antibodies specific for cancer-associated proliferating cellular nuclear antigen for tumor monitoring and diagnosis	Malaney C. Young, Ph.D.	Robert J. Hickey, Ph.D.
9 a.m. to noon	Poster Session	Section 31	Predictive Biomarkers 3	2043	12	Circulating tumor DNA (ctDNA) mutation analysis at baseline (BSL) and end of treatment (EOT) with sacituzumab govitecan (SG) and clinical impact on efficacy in patients with HR+/HER2- metastatic breast cancer (mBC): Biomarker results from TROPiCS-02	Hope S. Rugo, M.D.	
9 a.m. to noon	Poster Session	Section 31	Predictive Biomarkers 3	2047	16	Homologous recombination deficiency in lung cancer in the INSPIRE study	Katherine G. Roth, M.D.	Stephen B. Gruber, M.D., Ph.D., M.P.H.
9 a.m. to noon	Poster Session	Section 49	Phase 0 and Phase I Clinical Trials	CT032	11	Phase 1/2 trial of the TBL1 inhibitor, tegavivint, in advanced hepatocellular carcinoma (aHCC)		Daneng Li, M.D.
12:30 to 1:45 p.m.	Special Session	Room S106 — McCormick Place South (Level 1)	AACR Annual Business Meeting of Members	SS08		AACR Treasurer-Elect	Michael A. Caligiuri, M.D.	
1:25 to 1:45 p.m.	Advances in Diagnostics and Therapeutics	Arie Crown Theater — McCormick Lakeside Center (Level 2)	Challenges and Opportunities in the Development of Next Generation Antibody Drug Conjugates	ADT04		Managing and predicting toxicities from new and emerging ADCs	Hope S. Rugo, M.D.	
2 to 5 p.m.	Poster Session	Section 6	Microenvironment-Driven Cancer Evolution	2670	8	Understanding cell-of-origin influence on cancer-associated fibroblasts in lung adenocarcinoma	Minxiao Yang, M.S.	Crystal N. Marconett, Ph.D.
2 to 5 p.m.	Poster Session	Section 12	microRNAs and Other Noncoding RNAs 2	2807	23	Determining a role for a long noncoding RNA involved in the DNA damage response of lung adenocarcinoma	Michele Ramos Correa	Crystal N. Marconett, Ph.D.
2 to 5 p.m.	Poster Session	Section 28	Immune Checkpoints	3231	27	Inhibition of focal adhesion kinase enhances antitumor response of immune checkpoint inhibitor therapy in laryngeal cancer	Atish Ranjan Mohanty, Ph.D.	
2 to 5 p.m.	Poster Session	Section 30	Modifiers of the Tumor Microenvironment	3286	18	Targeting ALKBH5 to enhance the anti-tumor immunity of natural killer cells	Yuan Che, Ph.D.	Jianjun Chen, Ph.D.

All sessions are listed in Central Daylight Time. Schedules and locations are subject to change by AACR.

MONDAY, APRIL 28, 2025

Time	Session Type	Location	Session Title	Presentation No.	Poster Board No.	Publishing Title	First Author/Presenter	Last Author
2 to 5 p.m.	Poster Session	Section 32	Prognostic Biomarkers 2	3338	8	A CpG methylation based epigenetic signature for recurrence prediction in stage II/III colorectal cancer: The CENSURE Study	Caiming Xu, Ph.D.	Ajay Goel, Ph.D.
2:35 to 2:50 p.m.	Minisymposium	Room E350 — McCormick Lakeside Center (Level 3)	Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases	3742		Multi-omics analysis of MYC gene and WNT signaling pathway alterations in early-onset colorectal cancer in Hispanic/Latino patients, enhanced with spatial transcriptomics approaches	Francisco Gutierrez Carranza	Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

TUESDAY, APRIL 29, 2025

9 a.m. to noon	Poster Session	Section 2	Approaches for Metastasis Inhibition	3864	7	AOH1996: A multi-faceted inhibitor of metastasis via PCNA and tumor microenvironment targeting	Robert G. Lingeman	
9 a.m. to noon	Poster Session	Section 11	Integrating Chromatin, Oncogenes, DNA Repair, and Biomarkers for Therapeutic Advancements	4100	7	Aberrant translation regulated by METTL1/WDR4-mediated Val-AAC tRNA N7-methylguanosine modification promotes gastric carcinogenesis	Yuan Li, Ph.D.	Ajay Goel, Ph.D.
9 a.m. to noon	Poster Session	Section 16	HDAC and Methyltransferase Inhibitors	4235	21	PCNA and histone deacetylase targeted inhibitors in cutaneous T-cell lymphoma	Caroline M. Li, Ph.D.	Linda H. Malkas, Ph.D.
9 a.m. to noon	Poster Session	Section 23	Reversal of Drug Resistance 2	4453	24	Glucagon-like peptide-1 receptor agonists target the HIF1 α -PFKFB3 pathway to enhance Lenvatinib efficacy and overcome resistance in hepatocellular carcinoma through the reversal of the Warburg effect	Takayuki Noma, M.D.	Ajay Goel, Ph.D.
9 a.m. to noon	Poster Session	Section 29	Liquid Biopsy: Circulating Nucleic Acids 2	4562	15	Bespoke sequencing of enriched and normalized amplicons increases on-target rate and reduces background noise for circulating tumor DNA detection and quantification	Tania Contente-Cuomo (TGen)	
9 a.m. to noon	Poster Session	Section 34	Targeted Therapies and Combinations 2	4706	4	Evaluating the efficacy of RAS(ON) inhibitor RMC-6236 combined with chemotherapy and other targeted therapies in 3D models involving patients with KRAS-mutated pancreatic cancer		Sunil Sharma, M.D., M.B.A. (TGen)
9 a.m. to noon	Poster Session	Section 38	Epigenetic Regulation of Tumor Immunity	4843	13	TET2 oxidizes chromatin-associated regulatory RNA m5C to potentiate anti-tumor immunity	Ying Qing, Ph.D.	Jianjun Chen, Ph.D.
9 a.m. to noon	Poster Session	Section 43	Health Disparities across the Cancer Continuum	4971	18	Predicting lung cancer screening adherence among underserved and minoritized communities using social determinants and neighborhood factors		Loretta Erhunmwunsee, M.D.
9 a.m. to noon	Poster Session	Section 45	Multi-modal Analysis and Multi-omics Characterization	5011	15	Integrating multimodal data with survival-based variational autoencoders to predict recurrence-free survival in breast cancer	Sydney Grant, Ph.D.	Aritro Nath, Ph.D.
9 a.m. to noon	Poster Session	Section 48	First-in-Human Phase I Clinical Trials 2	CT157	23	Phase 1 dose-escalation study of linclatamig, a LY6G6D \times CD3 T cell-engaging bispecific antibody, in patients with colorectal cancer	Marwan Fakh, M.D.	
9 a.m. to noon	Poster Session	Section 50	Phase I Clinical Trials in Progress 2	CT187	4	A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor (CAR) γ δ T cell therapy, in patients with relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC) (trial in progress)	Sumanta K. Pal, M.D.	
11:01 to 11:11 a.m.	Clinical Trials Plenary Session	Arie Crown Theater — McCormick Lakeside Center (Level 2)	Biologics and T-cell Engagers	CTPL04		Discussant	Hope S. Rugo, M.D.	

All sessions are listed in Central Daylight Time. Schedules and locations are subject to change by AACR.

TUESDAY, APRIL 29, 2025

Time	Session Type	Location	Session Title	Presentation No.	Poster Board No.	Publishing Title	First Author/Presenter	Last Author
2 to 5 p.m.	Poster Session	Section 1	A Role for the Tumor Microenvironment in Progression	5103	8	Digital spatial profiling with GeoMx to identify differential protein expression in Non-Hispanic/Latino and Hispanic/Latino Patients with metastatic hormone sensitive prostate cancer	Peter D. Zang, M.D.	Tanya B. Dorff, M.D.
2 to 5 p.m.	Poster Session	Section 2	Molecular Regulation of EMT	5133	11	End-stage breast cancer metastases manifest as two subtypes with distinct dissemination patterns, proliferation/EMT signatures, and immune microenvironments	Isaac Bishara, Ph.D.	
2 to 5 p.m.	Poster Session	Section 2	Molecular Regulation of EMT	5140	18	Phenotypic plasticity and cellular decision-making: role of SLIT2 in epithelial-to-mesenchymal transition	Sravani Ramisetty	Ravi Salgia, M.D., Ph.D.
2 to 5 p.m.	Poster Session	Section 8	Where's Waldo: Spatial Complexity of the Tumor Microenvironment 2	5322	28	Spatial profiling of the tumor microenvironment in colorectal cancer: Insights into immune, tumor, and stromal interactions using high-dimensional protein analysis	Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.	
2 to 5 p.m.	Poster Session	Section 11	Genomic Profiling of Tumors 1	5359	13	Multi-omics characterization of copy number variation in high-grade serous ovarian cancer	Yuxin Jin, M.S.	Rania Bassiouni, Ph.D.
2 to 5 p.m.	Poster Session	Section 12	Metabolic Reprogramming	5394	22	Transcriptional reprogramming, metabolic rewiring and tumor immune microenvironment (TIME) reconfiguration: investigating the molecular underpinnings of GRAMD2+AT1 cell-derived murine LUAD	Angel P. Hunt	Crystal N. Marconett, Ph.D.
2 to 5 p.m.	Poster Session	Section 21	Novel Antitumor Agents 3	5645	23	Targeting transcription-replication conflict for selective chemotherapy in glioblastoma	Long Gu, Ph.D.	Linda H. Malkas, Ph.D.
3:05 to 3:20 p.m.	Minisymposium	Room E450 B - McCormick Lakeside Center (Level 4)	Experimental Therapeutics: Drug Resistance	6383		Overcoming intrinsic mechanisms of cell cycle inhibitor resistance in estrogen receptor-positive (ER+) breast cancer	Kimya L. Karimi	Andrea H. Bild, Ph.D.

WEDNESDAY, APRIL 30, 2025

8 to 10 a.m.	Plenary Session	Arie Crown Theater — McCormick Lakeside Center (Level 2)	Opportunities in Predictive Oncology	PL05		Chair, Chair Introduction and Wrap Up	David W. Craig, Ph.D.	
9 a.m. to noon	Poster Session	Section 10	Genomic Profiling of Tumors 3	6630	11	Ancestry and lung adenocarcinoma: exploring ancestry-associated variations in tumor metabolism, mitochondrial dysfunction, and immune dynamics	Yuxin Jin	Aaron Neely, Ph.D., M.S., M.Sc.
9 a.m. to noon	Poster Session	Section 18	Drug Resistance in Molecular Targeted Therapies 5	6802	14	RLIP depletion promotes apoptosis in ovarian cancer	Sharad S. Singhal, Ph.D.	Ravi Salgia, M.D., Ph.D.
9 a.m. to noon	Poster Session	Section 21	Novel Antitumor Agents 4	6865	9	Discovery and characterization of small molecule inhibitors targeting EXO1 for BRCAness cancer therapy	Yixing Wang	Binghui Shen, Ph.D.
9 a.m. to noon	Poster Session	Section 25	Lead Identification and Optimization	6989	18	Advancing AOH1996: Enhanced anticancer activity of next-generation small molecule PCNA inhibitors	Pouya Haratipour	Robert J. Hickey, Ph.D.

All sessions are listed in Central Daylight Time. Schedules and locations are subject to change by AACR.

WEDNESDAY, APRIL 30, 2025

Time	Session Type	Location	Session Title	Presentation No.	Poster Board No.	Publishing Title	First Author/Presenter	Last Author
9 a.m. to noon	Poster Session	Section 25	Lead Identification and Optimization	6996	25	Integrating high-throughput screening with ligand-based pharmacophore modeling and virtual screening strategies to optimize exonuclease 1 inhibitor design	Jessica Hess, Ph.D.	Binghui Shen, Ph.D.
9 a.m. to noon	Poster Session	Section 32	Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1	7162	26	Association between circulating B cell subtypes and treatment response in patients with metastatic renal cell carcinoma (mRCC)		Sumanta K. Pal, M.D.
9 a.m. to noon	Poster Session	Section 32	Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1	7164	28	Predictive biomarkers and immune dynamics in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab	Jian Ye	Marwan Fakh, M.D.
9 a.m. to noon	Poster Session	Section 34	Molecular Genetics and Epigenetics of Tumors	7183	14	METTL1-mediated m7G modification promotes 5-FU resistance in colorectal carcinoma	Silei Sui, Ph.D.	Ajay Goel, Ph.D.
9 a.m. to noon	Poster Session	Section 35	Targeted Therapies and Combinations 4	7196	2	Synergistic effect of sotorasib plus trametinib in patients with KRASG12C-mutated metastatic colorectal cancer	Silei Sui, Ph.D.	Ajay Goel, Ph.D.
9 a.m. to noon	Poster Session	Section 35	Targeted Therapies and Combinations 4	7199	5	Synergistic anticancer effects of milciclib and mirdametinib: mechanistic insights into cell cycle arrest, DNA damage and senescence	Xinyu Pei	
9 a.m. to noon	Poster Session	Section 38	Novel In Vivo, In Vitro, and In Silico Models	7261	8	Dynamical mathematical models reveal that cell cycle inhibitors promote immunogenicity and T cell cytotoxicity when combined with IL-15 in estrogen receptor positive breast cancer cell lines		Kimya Karimi
9 a.m. to noon	Poster Session	Section 45	Identification of New Cancer Vulnerabilities Through Convergence Science	7459	4	The anticancer effects of brusatol are mediated by PPAR- γ /ME1-driven glycolysis in intrahepatic cholangiocarcinoma	Xiaoqing Wang, M.D., Ph.D.	
9 a.m. to noon	Poster Session	Section 46	Tumor Evolution, Clonal Progression, and Spatiotemporal Dynamics	7494	7	An integrative systems-level framework reveals SMARCD3 resistance regulon signatures vulnerable to MEK1/2 inhibitors in ER+BC cells resistant to everolimus	Eric F. Medina	Aritro Nath, Ph.D.

Refer a Patient

Referral requests can be made via phone, email or by visiting EpicCare Link.

City of Hope Southern California Clinical Network

PHONE 800-826-HOPE (4673) **FAX** 844-264-4357

EMAIL socalnewpatientreferrals@coh.org

City of Hope Orange County Lennar Foundation Cancer Center

PHONE 866-408-1263 **FAX** 949-777-6750

EMAIL ocphysicianrelations@coh.org

City of Hope Cancer Center Atlanta

PHONE 770-400-6568 **FAX** 770-400-6900

EMAIL gareferrals@coh.org

City of Hope Cancer Center Chicago

PHONE 847-746-9990 **FAX** 847-342-4089

EMAIL referrals@coh.org

City of Hope Cancer Center Phoenix

PHONE 623-207-3241 **FAX** 623-932-8631

EMAIL azreferrals@coh.org

International only

PHONE +1-833-330-HOPE (4673)

EMAIL internationalpatientcare@coh.org

EpicCare Link is City of Hope's referring physician online portal. View lab results, imaging reports, visit summaries, medications, procedures, allergies and most other clinical documentation in the patients' charts. Upload relevant patient level documents to be reviewed by City of Hope's administrative team for inclusion in the patients' City of Hope chart. Request your EpicCare Link account at cityofhope.org/epiccare.

City of Hope Networking Reception

R.S.V.P. NOW FOR AN EVENING WITH CITY OF HOPE®

Monday, April 28, 2025

7 to 9 p.m. CDT

Ritz Carlton, Water Tower Place,
160 E Pearson St, Chicago, IL 60611
Ritz Carlton Ballroom

cityofhope.org/aacr25



Meet and Greet With Our Renowned Experts

COME VISIT US AT BOOTH NO. 2805 IN THE EXHIBITION HALL!

Monday, April 28

11 to 11:30 a.m. CDT



Walter Stadler, M.D., F.A.C.P.

Chief Clinical Officer, City of Hope Cancer Center Chicago, Professor, Department of Medical Oncology & Therapeutics Research, Medical Oncologist

Expert in advanced treatments for prostate, bladder, kidney and testicular cancer



David Craig, Ph.D.

Professor and Chair, Department of Integrative Translational Sciences; Deputy Director of Translational Sciences in Beckman Research Institute of City of Hope; Associate Director of Data Science, Comprehensive Cancer Center

Expert in translational genomics, bioinformatics, biomedical information and information integration



Loretta Erhunmwunsee, M.D.

Vice President, Chief Health Access and Community Enrichment Officer

Expert on thoracic surgery and addressing health disparities in cancer treatment



Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S.

Assistant Professor, Department of Integrative Translational Sciences

Expert in translational multi-omics research and colorectal cancer disparities in Hispanic/Latino communities



*Our National Cancer Institute-designated comprehensive cancer center near Los Angeles has repeatedly been ranked by U.S. News & World Report among the nation's best hospitals for cancer.